This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Yes i thought the same GF, thats not playing on a level field for some..JB..

Well MMGs fighting back, if we are to beleive the buy and sell figures we have more shares bought than sold.

cheers GF.

Lets just hope the markets settle down before the good news comes out.
DB66

Wish I'd stayed in bed. I'm with you GF. There are a few things the LSE should sort out.

Found this from you know where.

Insinger short term price target is 275p

Optimist at large - 18 Apr'05 - 07:06 - 5052 of 5062


MEDICAL MARKETING INTERNATIONAL GROUP PLC


NOTIFICATION OF R&D DAY

Date: Tuesday 26 April 2005

Medical Marketing International Group plc (LSE: MMG), the Cambridge, UK-based
pharmaceutical development company announces that it is to hold an R&D day on
Tuesday 26 April, 2005 at Buchanan Communications, 107 Cheapside, London EC2V
6DN.


MMI is an emerging UK-based biopharmaceutical company focussed principally on
the development of potential therapies in commercially attractive therapeutic
areas, such as cancer and infectious disease.


The presentations will focus primarily on two of MMI's key therapeutic programs,
from the joint venture Genvax and the wholly owned subsidiary Oncosense.
Genvax's development of cancer therapies is based on a proprietary DNA vaccine
platform technology about which clinical trials data has recently been
announced. Oncosense is focused on developing anticancer technologies, using
organo-metal compounds of the precious metal ruthenium as cytotoxic drugs.


An overview on Genvax's vaccine technology will be given by Freda Stevenson,
Professor of Immunology at the University of Southampton and a world-renowned
expert on DNA cancer vaccines. An overview on the scientific developments in
ruthenium compounds will be presented by Peter Sadler, Crum Brown Chair of
Chemistry at the University of Edinburgh, who is a leading authority on
organo-metallic chemistry with medical application.


Commenting on the forthcoming R&D Day, David Best, Chairman of MMI said: "The
team at MMI is extremely excited to be holding its first R&D day. Importantly,
the world class experts Professors Stevenson and Sadler as inventors of these
technologies describe some of the exciting products that are being progressed in
MMI's therapeutic portfolio. The R&D day will also be attended by key people
from the MMI team who will be available to answer questions. We hope that this R
&D day will lead to investors being better informed about MMI."

For further information, please contact:

David Best, Chairman
MMI Group Tel: +44 (0)1223 477677
www.mmigroup.co.uk

Lisa Baderoon/Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000

MS

Good find Mickey. Still has the potential to jump back intothe blue this one, like it did friday. Buys outnumber sells if the figures are correct.

cheers GF.

Buyers certainly coming back in now and its moved up again.

cheers GF.

dows up a tad....... should see our small caps back up now.... fingers crossed
rob

bugger..... now its down.sorry

No late run up from this one yet, mind theres still time.

cheers GF

considering the dow is now southward bound mmg is holding up well
rob

The last but one Insinger note, we know they have now updated to 275p.


Insinger de Beaufort 131 Finsbury Pavement
Tel +44 (0) 20 7190 7000 London
www.insinger.com EC2A 1NT
UK Equity Research 22 February 2005
Trading View
Independent Banking
Source: Insinger de Beaufort, Bloomberg

Accelerating development pipeline

Significant commercial potential: MMI is an emerging biotechnology company
focused in cancer and infectious diseases, both areas of significant commercial
potential. MMIs strategy is to develop drugs to Phase II clinical trial stage and then
commercialise via out-licencing agreements with pharmaceutical companies. Thin
pipelines and patent expiries have acted as a catalyst for a large number of deals
with small cap biotechs such as MMI, even for products which are relatively early
stage. For example a deal with Oxxon Therapeutics could potentially be worth up to
44m in up-front and milestone payments in order to access Xenovas early stage
cancer DISC HSV vector technology. It is also interesting to note recent benchmark
deals for pre clinical early stage compounds with promise - Novartis paid c.$157m to
Xenon and J&J is paying up to $295m in a deal excluding royalties to Arena.
MMI has four R&D divisions:
a) Oncosense (wholly owned) - technology based around the precious metal
ruthenium which is potentially up to 15 times more efficacious than the
most potent platinum anticancer drug.
b) Genvax (JV) - developing DNA vaccines for cancer with Southampton
University/Cancer Research UK Leukaemia Research Fund
c) Viratis (JV) - viral infections with Kings College London
d) Endozyme (wholly owned) - drug resistant Infections working with
Cambridge University/Novartis
MMI also provides technical services to UK academic and commercial institutions
which apart from generating revenues, also provides a stream of potential in -
licensing opportunities.
Tight cost control: Given a current cash balance of 2.6m, MMI has enough cash to
last until Q1 06. Whilst it would not be prudent to discount a future fund raising,
additional cash inflows may come from licensing deals. Furthermore MMIs R&D
expenses are contained via collaborat ions outlined above and also contracting out
to CROs (clinical research organisations).
Strong management: MMIs management has been strengthened recently with the
appointment of Dr James Hoeschele (co-discoverer of Carboplatin, a platinum based
anti-cancer treatment) to work on MMI's leading ruthenium compounds which are
expected to reach the market during 2008.
Strong newslow: During the course of 2005 MMI aims to bring 6 new products into
Phase I/II clinical trials including compounds from MMIs ruthenium based
anticancer programme. The JV Genvax is due to report on Phase II trials treating
follicular lymphoma on the 18th March. These results are expected to be positive
and as such could drive the share price higher despite the recent good run. MMI is
also currently negotiating with a number of potential licensee companies for the
ruthenium technology. Conservative target price of 200p (DCF) generates 50% plus.


cheers GF.

A positive start for MMG lets hope with a week to go to the company R&D day that the stock picks up in price and blasts through 200p.

cheers GF.

Bought myself a few more not a lot, NICE.

cheers GF.

Looking to top up on one of my stocks too GF. Either MMG, VML, or MOI. Any suggestions?

Chad MMG if you ask on this thread :o). Personally I think this is set to rocket in the next month despite the market conditions. Agreed GF?

I think it will rise up to the R@D day as long as we dont get bad results this evening in the US RE TO INTEL. lOOKS TO ME LIKE A LOT ARE WAITING FOR DIRECTION IN THE MARKET AT PRESENT. sorry about the caps lock, got to go.

cheers GF.

From the other place. A bit long but worth a read.


DAFAD - 19 Apr'05 - 07:13 - 5077 of 5082


RNS Number:2124L
Medical Marketing Int'l Group PLC
19 April 2005


For Immediate Release 19 April 2005


Medical Marketing International Group plc


MORE GLOBAL LEADERS PARTNER MMI'S LABHOTEL

"OFFICAL LABHOTEL OPENING IN CAMBRDIGE ON WEDNESDAY 27 APRIL 2005"

Medical Marketing International Group plc (MMI), (LSE: MMG), the Cambridge,
UK-based pharmaceutical development company focussed on commercially attractive
therapeutic areas such as cancer and infection announces that four more
global-leading laboratory equipment manufacturers have become 'partners' to
MMI's LabHotel.

The new LabHotel 'partners' are Invitrogen, New Brunswick Scientific, Associates
of Cape Code Inc, and VWR International. Existing LabHotel partners include Pall
Corporation and Corbett Research. In addition to these global-leading laboratory
equipment manufacturers, service providers such as The Royal Bank of Scotland
Group, one of the worlds largest banks, and Mewburn Ellis, Europes largest
biotechnology patent firm are also supporting LabHotel by providing special
terms for client companies.

Commenting on these new agreements, David Best, Chairman of MMI Group said: "The
latest partnership with more global leading businesses is a further endorsement
of MMI's business model. In return for MMI showcasing these products and
services in its LabHotel, we gain free access to extremely valuable equipment
that our biobabies such as Genvax and Oncosense need to use. In addition,
LabHotel enables other young biotech companies to use the equipment thereby
generating income for MMI. These two aspects of LabHotel contribute to MMI's
comparatively low burn-rate for a company that already has its Genvax DNA
vaccines in four clinical trials and expects to have some ten clinical trials
for cancer therapies ongoing this year."



For further information, please contact:

David Best - Chairman
MMI Group Tel: +44 (0)1223 477677
www.mmigroup.co.uk


Lisa Baderoon/Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000



Notes for Editors:


About MMI:

Medical Marketing International Group (MMI) is an emerging UK-based
biopharmaceutical company focussed principally on the development of potential

therapies in commercially attractive therapeutic areas, such as cancer,
infectious diseases, rheumatoid arthritis and asthma. The Group also offers a
range of technical support services to UK academic and commercial bodies, which
generate revenue and provide a flow of new potential in-licensing opportunities.
Further information regarding MMI can be found on-line at www.mmigroup.co.uk


About The Royal Bank of Scotland Group (RBS):

RBS is one of the worlds largest banks. NatWest is part of RBS. Valerie Dring
OBE, Associate Director of Business Development at Natwest commented: "MMI is an
innovative company with long-term vision and the new LabHotel's venture is a
testament to its ability to grown and change in a competitive and highly
specialised market. The strengths of MMI Group were recognised back in the early
1990s by the technology specialists at NatWest Commercial Banking in Cambridge,
and the relationship between them has continued through to today. MMI is a
valued customer with an excellent product offering. We are delighted to support
the team and congratulate them on the new LabHotel development which will bring
pioneering ideas and products to the region. NatWest is dedicated to supporting
Cambridge Technology businesses, which continue to lead the way in innovation
and expertise."


VWR International

"VWR International are a market leading global laboratory supply business, with
250,000 customers, over 6000 employees and operating within 18 countries. We are
privileged to be able to support the activities of MMI.

Being preferred supplier to the ERBI, biotechnology partnering network in the
Cambridge region VWRI have been fortunate enough to work with the MMI team on
the new purpose designed facilities, we have been extremely impressed with the
professional approach of Mr Dearsley and MMI.

Product performance, delivery schedules etc have been given fantastic
attention to detail to ensure the individual scientist is able to come in and
start work on day one. VWR have truly recognised the value that this unique
concept brings to the scientific community in Cambridge, and hence were
delighted to accept the offer to partner MMI in its unique venture".

Lisa Johnson, Account Manager


Associates of Cape Cod, Inc

"For over 30 years, Associates of Cape Cod, Inc. (ACC) has been a leading global
supplier of analyte detection products, including Limulus Amebocyte Lysate (LAL)
for the detection and quantification of bacterial endotoxins. ACC was the first
manufacturer licensed by the FDA to manufacture LAL for use as a quality control
test for endotoxin in the pharmaceutical and medical device markets. ACC has a
strong technical support and training ethos and feels that the LabHotel concept
is the perfect base for up and coming biotech and pharma business ideas. ACC
wants to offer its expertise to these companies to help them realise their
goals".

Mark Childs, UK Manager


Invitrogen

"Invitrogen, providers of High Quality and Innovative Products and Services to
the Life Science Industry, is delighted to collaborate with MMI in LabHotel.
This fits perfectly with our mission to accelerate research by delivering key
and innovative tools to the hands of Research Scientists, such as those who will
pass through LabHotel".

Andrew Barber, European Product Manager


New Brunswick Scientific

New Brunswick Scientific (NBS) is a world leader specialising in the manufacture
of research through production-scale equipment for culture growth, detection and
storage.


Pall Corporation

"Pall Life Sciences is part of Pall Corporation, the largest and most diverse
filtration, separation and purification company in the world, and a global
leader in the supply of separation and purification technologies for the
production of biotechnology and biopharmaceutical products.

Pall is proud to support MMI LabHotel, and assist biotech companies in the
critical process of new product development."

Tony Orchard, Marketing Vice President


Corbett Research

Corbett Research is an Australian Biotechnology company at the forefront of the
development of genetic analysis laboratory equipment. "The Lab Hotel is the
ideal venue for us as an organisation to showcase our latest equipment and to
work with emerging companies to help them develop new technologies".

John Corbett, Director of Corbett Research


Mewburn Ellis LLP

"As one of the longest established providers of intellectual property services
in the Cambridge area, Mewburn Ellis LLP welcomes MMI's initiative in support of
the development of the biotechnology industry in the region and wishes them
success in the establishment of LabHotel"

Adrian Brasnett, Partner


This information is provided by RNS
The company news service from the London Stock Exchange
END

MS

More good news then Mickey, itl all add up when investors get their confidence back. If we gwet today away and we have good news from Intel it will add to the better than expected inflation news in the US and we will be away again.

cheers GF.

Thanks Mickey. good post.
We crept past my last buy price today (just), showing tremendous resiliance.
But please everybody do not forget how many products this company has on trial.... this really is retirement material.
Keeping the faith...... Rob